TL;DR
Get health and wellness essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
More than 5,000 otolaryngologists are expected at the AAO-HNSF 2026 Annual Meeting in Los Angeles from Oct. 17-20, where hearing health will feature across several research tracks. Planned topics include links between hearing loss and diabetes or cognitive decline, questions about GLP-1 medications, gene therapy for genetic hearing loss, and proposed Medicare payment cuts.
Hearing health will feature prominently at the American Academy of Otolaryngology–Head and Neck Surgery Foundation’s 2026 Annual Meeting and OTO Expo, scheduled for Oct. 17-20 in Los Angeles. More than 5,000 otolaryngologists are expected to attend, with planned research addressing hearing loss alongside type 2 diabetes, cognitive decline, healthy aging and emerging treatments.
The meeting’s media guide names “hearing health becomes brain health” as one of six research frontiers. The program is set to examine connections among hearing loss, type 2 diabetes and cognitive decline, as well as the role of hearing in healthy aging. These are subjects scheduled for discussion; the source material does not report results from the meeting itself, which has not yet taken place.
Another topic is the expanding use of GLP-1 and GIP/GLP-1 medications. The Hearing Review reports that ENT specialists are examining questions involving these drugs, including thyroid cancer risk, cancer aggressiveness, obesity-related airway disease, surgical outcomes and patient counseling. For hearing care professionals, the issue is relevant because people with obesity and type 2 diabetes are populations already associated with elevated hearing-loss risk. The source describes downstream effects of these medicines on hearing as an emerging area of inquiry, not an established drug effect.
The agenda also includes early gene therapy trial results for genetic hearing loss, including work on AK-OTOF and DB-OTO. The report says studies suggest children with profound genetic hearing loss may gain access to sound and new opportunities for speech and language development. It also points to research on preventable noise exposure, including whether seating location at concert venues affects exposure and hearing symptoms.
Hearing Care Meets Whole-Body Health
The meeting’s planned research reflects a wider clinical question: how hearing care fits into the management of health conditions that can affect more than one system. Hearing loss, diabetes and cognitive decline are being considered together in the program, putting audiologic care into conversations about aging and broader health rather than treating it as an isolated concern.
This matters to clinicians because patients may have overlapping health risks and care needs. The growing use of GLP-1 medicines adds questions for counseling and clinical practice, but the source does not establish that these medicines cause or prevent hearing loss. Discussion at the meeting may help define which questions researchers and clinicians need to investigate; specific answers remain to be seen.
The agenda also has potential relevance for families affected by inherited hearing loss. Early trial findings for AK-OTOF and DB-OTO point to possible gains in sound access for children with profound genetic hearing loss. The source frames these as early results and possible developmental opportunities, rather than a guarantee of benefit for every child.
Research Builds on Earlier Findings
The planned sessions build on earlier work linking type 2 diabetes with increased risk of sensorineural hearing loss. The Hearing Review has also covered how chronic illnesses can affect hearing, balance and cognition, and has published clinical recommendations for hearing care professionals addressing cognition.
The article points to a study published earlier in 2026 that linked hearing aid use to a 23% lower dementia risk among adults with epilepsy and hearing loss. That finding concerns a particular study population and should not be read as proof that hearing aids prevent dementia for everyone. The source also cites a separate survey identifying hearing health as a longevity blind spot among consumers and clinicians. It does not provide the survey’s sample or methodology in the supplied material.
Policy concerns form another strand of the meeting’s backdrop. The Centers for Medicare & Medicaid Services has proposed 50% Medicare payment cuts for certain same-day services beginning in 2027. The Hearing Review reports that a survey found eight in 10 ENTs said the proposed cut could limit seniors’ access to specialty care. The proposal is a policy prospect, not a cut already in effect.
““Otolaryngology is at the center of some of today’s most important health and policy conversations.””
— Rahul K. Shah, MD, MBA, Academy CEO and executive vice president
Questions Await Meeting Data
The meeting is still upcoming, so the presentations’ findings and details have not yet been reported in the supplied source. It does not list individual study authors, sample sizes, methods or full results for the research tracks described. The precise nature of any relationship between GLP-1 medicines and auditory health remains an open research question.
The source also does not specify which gene therapy results will be presented, how long participants were followed, or how broadly the findings may apply. The status of the proposed Medicare payment cuts could change as policy decisions proceed. The reported survey concern reflects respondents’ views about potential access effects, not a measured change in access already caused by the proposal.
Los Angeles Meeting in October
The AAO-HNSF Annual Meeting and OTO Expo is scheduled to convene in Los Angeles from Oct. 17 through Oct. 20, 2026. The studies and policy topics described in the media guide are expected to be discussed there. Members can register through the meeting’s registration page, according to The Hearing Review.
After the presentations, fuller study details will be needed to assess what the research supports, including methods, participant groups and the limits of each finding. Policy developments around the proposed 2027 Medicare changes will also determine whether and how payment rules change. The source does not provide a timeline for those decisions.
Key Questions
When and where is the AAO-HNSF 2026 Annual Meeting?
It is scheduled for Oct. 17-20, 2026, in Los Angeles.
What hearing topics are on the program?
Planned topics include links between hearing loss, type 2 diabetes and cognitive decline; healthy aging; GLP-1 medications; noise exposure; and gene therapy research for genetic hearing loss.
Does the report show that GLP-1 drugs affect hearing?
No. It describes auditory health effects as an emerging research question. The supplied material does not establish that the medicines cause or prevent hearing loss.
Have the gene therapy studies established a treatment benefit?
The report describes early results from studies of AK-OTOF and DB-OTO that suggest children with profound genetic hearing loss may gain access to sound. It does not provide enough study detail to establish how broadly those results apply.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
